Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P02462: Variant p.Gly1041Glu

Collagen alpha-1(IV) chain
Gene: COL4A1
Feedback?
Variant information Variant position: help 1041 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glycine (G) to Glutamate (E) at position 1041 (G1041E, p.Gly1041Glu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from glycine (G) to medium size and acidic (E) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In SCHZC. Any additional useful information about the variant.


Sequence information Variant position: help 1041 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1669 The length of the canonical sequence.
Location on the sequence: help TPGEKGVPGIPGPQGSPGLP G DKGAKGEKGQAGPPGIGIPG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         TPGEK---GVPGIPGPQGSPGLPGDKGA------KGEKGQAGPPGI-GIPG

Mouse                         SPGEK---GVPGIPGSQGVPGSPGEKGA------KGEKGQS

Bovine                        MPGPK---GVAGIPGPQGIPGLPGDKGA------KGEKGQA

Caenorhabditis elegans        LKGES---GLPGLPGRQGNDGIPGQPGL------EGECGED

Drosophila                    QPGEKGSVGAPGIPGAPGMDGLPGAAGAPGAVGYPGDRGDK

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 173 – 1669 Collagen alpha-1(IV) chain
Region 173 – 1440 Triple-helical region
Region 504 – 1382 Disordered
Alternative sequence 520 – 1669 Missing. In isoform 2.



Literature citations
Phenotypic spectrum of COL4A1 mutations: porencephaly to schizencephaly.
Yoneda Y.; Haginoya K.; Kato M.; Osaka H.; Yokochi K.; Arai H.; Kakita A.; Yamamoto T.; Otsuki Y.; Shimizu S.; Wada T.; Koyama N.; Mino Y.; Kondo N.; Takahashi S.; Hirabayashi S.; Takanashi J.; Okumura A.; Kumagai T.; Hirai S.; Nabetani M.; Saitoh S.; Hattori A.; Yamasaki M.; Kumakura A.; Sugo Y.; Nishiyama K.; Miyatake S.; Tsurusaki Y.; Doi H.; Miyake N.; Matsumoto N.; Saitsu H.;
Ann. Neurol. 73:48-57(2013)
Cited for: INVOLVEMENT IN SCHZ; VARIANTS SCHZC ARG-655; ARG-870; SER-897; SER-948; GLU-1041; GLU-1082; ARG-1326; ASP-1332 AND LYS-1615;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.